1. Title page: Epidemiological analysis of 869,220 varicose vein surgeries over 12 years in Brazil: trends, costs and mortality rate.

Marcela Juliano Silva[a] MD, Andressa Cristina Sposato Louzada[a] MD, Marcelo Fiorelli Alexandrino da Silva[a] MD, Maria Fernanda Cassino Portugal[a] MD, Marcelo Passos Teivelis[a,b] MD, PhD, Nelson Wolosker[a,b,c] MD, PhD.

a. Hospital Israelita Albert Einstein

Address: Av. Albert Einstein, 627, Bloco A1, sala 423; ZIP Code 05652-900. Morumbi, São Paulo – SP, Brazil.

b. Faculdade Israelita de Ciências da Saúde Albert Einstein

Address: Av. Prof. Francisco Morato, 4293; Zip Code 05521-200. Butantã, São Paulo - SP, Brazil.

c. São Paulo University Medical School

Address**:** Av. Dr. Arnaldo, 455; Zip Code 01246903. Cerqueira César, - São Paulo, SP, Brazil.

2. Structured Abstract

Objectives: to assess the total numbers of surgical procedures performed between 2008 and 2019 for the treatment of varicose veins in the Public Health System, which exclusively insures more than 160 millions Brazilian, the distribution of the surgeries over time, as well as its costs and mortality rates.

Design, Materials and Methods: data referring to surgeries to treat chronic venous disease between 2008 and 2019 were extracted from the database of the Brazilian Public

Health System.

Results: In total, 869,220 surgeries were performed to treat chronic venous disease in public hospitals and outpatient clinics in Brazil, with an average rate of 4,52 surgeries per 10,000 inhabitants per year. From 2015 on, we observe a slight downward trend in the total number of procedures. The total amount reimbursed by the government was US$ 266,628,181.69. A total of 49 deaths were registered following varicose vein surgery, corresponding to a mortality rate of 0.005%.

Conclusions: a total of 869,220 surgeries were performed to treat varicose in twelve years, with an overall rate of 4.52 procedures per 10,000 inhabitants per year. The mortality rate was very low, 0.005%.

4. Abbreviation List

Chronic vein disease	CVD
United States of America	USA
Brazilian Public Health System	SUS

5. Introduction

Chronic vein disease (CVD) is very prevalent, progressive[1] and with relevant morbidity[2,3], leading to a high social, economic, and health burden[4–7].

The prevalence of CVD may be even greater than 50% of the population[8–10] and both the prevalence and the severity of CVD are expected to increase as the population ages[11,12]. Impairment of the patient's health and quality of life is evident in the advanced stages of the CVD, especially when they present with venous ulcers[13]. However, patients report poorer health-related quality of life even with uncomplicated CVD[3].

In addition to skin changes, inflammation, phlebitis and venous ulcers, other severe complications related to CVD are deep venous thrombosis[2] and varicose hemorrhage[14,15], which may be life-threatening. A review of the Forensic Science in South Australia found 8 cases of death due to hemorrhage from ruptured peripheral CVD over 10 years, with an estimated prevalence of 0.01% of all autopsy cases[14].

Furthermore, CVD represents a high social and economic burden. In the United States, CVD leads to 2 millions workdays missed each year and to early retirement[4], with a nationwide health care burden of more than $3 billion per year[5]. In Brazil, between 2005 and 2014, social security expenses with temporary disability due to CVD increased 3.5-fold, and more than 27 millions working days were lost[6].

The standard surgical treatment, which includes ligation and stripping of saphenous veins as well as varicose veins phlebectomies, is cost-effective[16–19]. Even though this is a well-established and widely performed procedure to treat such a prevalent and morbid disease, to our knowledge, only a few countries have nationwide studies analyzing procedure rates and mortality, namely: Japan, the United States of America (USA) and Portugal, all of three developed countries. In Japan, the Japanese Society for Vascular Surgery[20] registered 41,246 surgeries for the treatment of CVD in 2014, with

a zero 30-day mortality. In the USA, according to the American College of Surgeons - Quality Improvement Program[21], a total of 48,615 surgeries for CVD was performed between 2005 and 2017, with a 30-day mortality rate of 0.02%. In Portugal, 153,382 patients underwent surgery to treat CVD in public hospitals between 2004 and 2016, with an in-hospital mortality rate of 0.015%[22].

We believe that only population-level data generate real-world evidence, better supporting the health care. To that aim, series larger than those mentioned above may be necessary. Furthermore, each country should be aware of its own statistics and be able to compare them with those of others in order to better interpret the data and thus improve health assistance.

Therefore, the objective of the present study was to retrospectively assess the total numbers of surgical procedures performed between 2008 and 2019 for the treatment of CVD in the Brazilian Public Health System (SUS), which exclusively insures more than 160 millions Brazilian, the distribution of the 869,220 surgeries over time, as well as its costs and mortality rates.

6. Materials and methods:

Data were retrieved from the TabNet platform, a public health information application developed by DATASUS, the Health Informatics Department of the Brazilian Ministry of Health. The TabNet system provides open data regarding procedures performed within the Brazilian Public Health System, input by hospitals and outpatient clinics adequately accredited. This accreditation and the information registration are a prerequisite for governmental reimbursement for the procedures performed.

Information on vascular surgery procedures for the treatment of CVD was selected from 2008 to 2019 at the TabNet platform of Brazil. Data included geographic region, number of procedures performed, mortality within the index admission in the hospital or in the outpatient facility, and the amounts paid by the Public Health System.

Two types of procedure were assessed, according to coding as established by the management system for procedures and medications of the Brazilian Public Health System - SIGTAP (Sistema de Gerenciamento da Tabela de Procedimentos, Medicamentos e OPM): bilateral surgical treatment for CVD (04.06.02.056-6) and unilateral surgical treatment for CVD (04.06.02.057-4).

All data were collected from public access sites through computer programs of automated content access (web scraping). These automated navigation codes were programmed in Python language (v. 2.7.13, Beaverton – Oregon – USA) using the Windows 10 Single Language operational system. The data collection, platform field selection, and table adjustment steps were performed using the selenium-webdriver packages (v. 3.1.8, Selenium HQ, several collaborators worldwide) and pandas (v. 2.7.13, Lambda Foundry, Inc. e PyData Development Team, New York, USA). The Mozilla Firefox browser (v. 59.0.2, Mountain – California – USA) and geckodriver webdriver (v 0.18.0, Mozilla Corporation, Bournemouth, England) were used.

Following collection and treatment, all data were organized and grouped in a spreadsheet using the Microsoft Office Excel 2016® (v. 16.0.4456.1003, Redmond – Washington – USA) software. Remittance values in Brazilian Real (R$, the official Brazilian currency) were converted into US dollars (U$), using the exchange rate of the

31st of December of 2012, which is the study's median date and corresponds to U$ 1 = R$ 2,04.

This study was approved by the Ethics Committee of the Hospital Israelita Albert Einstein (CAAE: 35826320.2.0000.0071). All data provided by DATASUS and TabNet is open and deidentified. For this reason, the Institutional Council of Revision (Conselho de Revisão Institucional, IRB) exempted informed consent.

7. Results:

In total, 869,220 surgeries were performed to treat CVD in Brazilian public hospitals and outpatient clinics between 2008 and 2019. The number and frequency of CVD surgery throughout the years is shown in Table 1. Bilateral procedures were the most frequently performed, representing 61,68% of the surgeries.

The distribution of procedures rates per 10,000 inhabitants exclusively dependent on the public health system per year is shown in Graph 1. The total average rate was 4,52 surgeries for CVD treatment per 10,000 inhabitants per year. The year 2014 showed the highest rates. From 2015 on, we observe a slight overall decrement in the surgery rates.

Government reimbursement in each geographic region is shown in Table 2. The total amount invested by the government in VV surgeries between 2008 and 2019 was US$ 266,628,181.69. The overall average investment per surgery was US$ 307,00.

The overall average reimbursement per surgery per year in US dollars is depicted in Graph 2. When we analyze the yearly distribution of the amounts paid per surgery by the government, we observe that 2014 is precisely the year in which reimbursement was also the highest.

Total procedures, total deaths, and mortality rates by Brazilian geographic regions are presented in Table 3.

A total of 49 deaths within the index admission in the hospital or in the outpatient facility was registered following CVD surgery, representing an overall mortality rate of 0.005%.

The southeast region of Brazil performed more than half of the procedures and showed an intermediate mortality rate.

8. Discussion:

We observed that a total of 869,220 surgeries to treat CVD, including inpatient and outpatient ligation and stripping of saphenous veins and varicose veins phlebectomies, corresponding to the largest series of the most frequently performed vascular surgeries.

Bilateral procedures were the mostly performed, which is likely a reflection of public reimbursement and logistics in Brazil.

The overall standardized rate was 4,52 surgeries for CVD treatment per 10,000 population per year, which is similar to the ones observed in Japan[20] and in the United States when considering the Medicare enrollees[23], but at least 5 times smaller than the ones reported in some European countries such as Finland[24], Belgian[25], and Scotland[26]. Since the Brazilian prevalence of CVD is estimated to be high, 37,9% in men and 50,9% in women[27], the 5-fold higher rates of surgical procedures in these European countries can not be explained by a higher prevalence in a similar fashion. Health care is mostly publicly funded in Brazil, Finland[28], Belgium[29] and

Scotland[30], therefore payment source can not explain the difference either. A possibility to be studied is that the population of these European countries is much smaller than that of Brazil, the United States of America and Japan, so perhaps the logistics of treating a low-mortality disease such as CVD are easier.

Regarding the distribution of surgeries over time, in Brazil, we observed a slight decrease in the total surgical procedures performed under the Public Health System since 2015. This finding contrasts with the reports in the literature of a rising tendency to treat CVD surgically[20,25,26]. One possible explanation may be an increasing rate of ultrasound-guided sclerotherapy with polidocanol foam to treat CVD, an outpatient procedure that is also reimbursed by the Brazilian government but was not evaluated in our study. Concerning endovenous procedures, although they may be accounted for an upward trend in procedures performed to treat CVD in other countries currently[20,23], they are unlikely to influence the standard surgery rates in Brazil, as the Public Health System does not ordinarily reimburse them. Some patients may be seeking treatment for CVD in the private sector, as the waiting lists are often long in the SUS, but these patients probably do not represent a large sample, since most Brazilians exclusively insured by the SUS cannot afford to pay surgical treatments out of their pockets.

The average spent by the government per procedure was US$307,00. The average amount paid by the governments of China[31] and the United Kingdom[16] per surgery is at least twice as much the amount paid by the Brazilian government. Due to the limitations of the data collection, we were not able to distinguish the amount paid for unilateral and bilateral surgeries, or for inpatient or outpatient procedures, we have only access to an average amount. Moreover, the government's refund is based on a fixed

compensation table and may not reflect the actual hospital and outpatient expenses, which is another limitation of our study.

In the 869,220 surgeries performed to treat CVD, we observed 49 deaths within the index admission in the hospital or in the outpatient facility, corresponding to a mortality rate of 0.005%. This finding underlines the safety of the surgical treatment. To our knowledge, the only other population-based study for comparison was the one evaluating the data from Portuguese public hospitals, with an in-hospital mortality rate of 0.015%[22]. The other population-based studies that assessed deaths following CVD surgeries evaluated 30-day mortality[20,21]. The mortality rate for CVD surgeries in Portugal was three-fold higher. A possible explanation for this difference is that our series is almost six-fold larger, maybe better reflecting real-life statistics. Another explanation is that in Portugal, the surgery rate for CVD is more than double the one in Brazil, thus it is possible that they encompass more at-risk patients in Portugal. Nonetheless, both mortality rates are very low, which underlines the safety of the surgical treatment.

Still regarding mortality assessment, some limitations of our study are noteworthy. As our data are anonymous, we do not know the causes of death and follow-up is not possible, therefore, deaths after discharge were missed, and we are unable to calculate 30-day mortality, as performed in Japan[20] and USA[21]. Consequently, we may be observing more deaths related to anesthetics and bleeding complications and perhaps missing some pulmonary embolism-related deaths.

Limitations:

In addition to the limitations already mentioned: the inability to distinguish the amount paid for unilateral and bilateral surgeries and the surgeries which involved or not saphenous vein treatment, refund based on a fixed compensation table and the impossibility to follow up, some other limitations are worthy of note.

We only have data on total number of procedures performed, which possibly does not reflect the number of patients treated, as some patients may have undergone more than one procedure to treat CVD, such as two unilateral procedures or even re-interventions considering that the study period is large.

As inherent to a retrospective analysis using web scraping data collection, our study is limited by the loss of patient information and eventual miscoding of the administrative database, which should not be statistically significant, given the large size of our population.

Despite these limitations, this is a comprehensive analysis of the surgical treatment of CVD under the Brazilian Public Health System, with the largest series of the most frequently performed vascular surgery in the literature, granting real-life statistics with high external validity. Therefore we believe this study presents a valuable tool for a better understanding of the surgical management of CVD and highlights its safety in the real world.

Conclusions:

We observed a total of 869,220 surgeries performed to treat CVD over twelve years, with a rate of 4,52 procedures per 10,000 inhabitants per year. The mortality rate was very low, 0.005%.

9. Funding:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

10. References:

[1]   Lee AJ, Robertson LA, Boghossian SM, Allan PL, Ruckley CV, Fowkes FGR, et al. Progression of varicose veins and chronic venous insufficiency in the general population in the Edinburgh Vein Study. J Vasc Surg Venous Lymphat Disord 2015;3:18–26. https://doi.org/10.1016/j.jvsv.2014.09.008.
[2]   Chang S-L, Huang Y-L, Lee M-C, Hu S, Hsiao Y-C, Chang S-W, et al. Association of Varicose Veins With Incident Venous Thromboembolism and Peripheral Artery Disease. JAMA 2018;319:807. https://doi.org/10.1001/jama.2018.0246.
[3]   Darvall KAL, Bate GR, Adam DJ, Bradbury AW. Generic Health-related Quality of Life is Significantly Worse in Varicose Vein Patients with Lower Limb Symptoms Independent of Ceap Clinical Grade. Eur J Vasc Endovasc Surg 2012:4.
[4]   Kim Y, Png CYM, Sumpio BJ, DeCarlo CS, Dua A. Defining the human and health care costs of chronic venous insufficiency. Semin Vasc Surg 2021;34:59–64. https://doi.org/10.1053/j.semvascsurg.2021.02.007.
[5]   Ruckley CV. Socioeconomic Impact of Chronic Venous Insufficiency and Leg Ulcers. Angiology 1997;48:67–9. https://doi.org/10.1177/000331979704800111.
[6]   da Coelho RM, Nunes MAP, Gomes CVC, dos Viana IS, da Silva ÂM. Time trends and social security burden of temporary work disability due to chronic venous disease in Brazil. BMC Public Health 2020;20:477. https://doi.org/10.1186/s12889-020-08563-2.
[7]   Tsai S, Dubovoy A, Wainess R, Upchurch GR, Wakefield TW, Henke PK, et al. Severe Chronic Venous Insufficiency: Magnitude of the Problem and Consequences. Ann Vasc Surg 2005;19:7.
[8]   Carpentier PH, Maricq HR, Biro C, Ponçot-Makinen CO, Franco A. Prevalence, risk factors, and clinical patterns of chronic venous disorders of lower limbs: A population-based study in France. J Vasc Surg 2004;40:650–9. https://doi.org/10.1016/j.jvs.2004.07.025.
[9]   Criqui MH. Chronic Venous Disease in an Ethnically Diverse Population: The San Diego Population Study. Am J Epidemiol 2003;158:448–56. https://doi.org/10.1093/aje/kwg166.
[10] Zolotukhin IA, Seliverstov EI, Shevtsov YN, Avakiants IP, Nikishkov AS, Tatarintsev AM, et al. Prevalence and Risk Factors for Chronic Venous Disease in the General Russian Population. Eur J Vasc Endovasc Surg 2017;54:752–8. https://doi.org/10.1016/j.ejvs.2017.08.033.
[11] Davies AH. The Seriousness of Chronic Venous Disease: A Review of Real-World Evidence. Adv Ther 2019;36:5–12. https://doi.org/10.1007/s12325-019-0881-7.

[12] Porciunculla M de M, Leiderman DBD, Altenfeder R, Pereira CSB, Fioranelli A, Wolosker N, et al. Clinical, ultrasonographic and histological findings in varicose vein surgery. REV ASSOC MED BRAS n.d.:7.

[13] Joaquim FL, Cruz-Quintana F, Pereira ER. Impact of venous ulcers on patients' quality of life: an integrative review. Qual Life n.d.:9.

[14] Byard RW, Gilbert JD. The Incidence and Characteristic Features of Fatal Hemorrhage Due to Ruptured Varicose Veins. Am J Forensic Med Pathol 2007;28:4.

[15] Serra R, Ielapi N, Bevacqua E, Rizzuto A, De Caridi G, Massara M, et al. Haemorrhage from varicose veins and varicose ulceration: A systematic review. Int Wound J 2018;15:829–33. https://doi.org/10.1111/iwj.12934.

[16] Epstein D, Onida S, Bootun R, Ortega-Ortega M, Davies AH. Cost-Effectiveness of Current and Emerging Treatments of Varicose Veins. Value Health 2018;21:911–20. https://doi.org/10.1016/j.jval.2018.01.012.

[17] Biemans AAM. Comparing endovenous laser ablation, foam sclerotherapy, and conventional surgery for great saphenous varicose veins. J Vasc Surg 2013;58:9.

[18] Michaels J, Campbell W, Brazier J, MacIntyre J, Palfreyman S, Ratcliffe J, et al. The treatment of varicose veins (REACTIV trial) n.d.:198.

[19] Mendes C, Martins A, Fukuda J, Parente J, Munia M, Fioranelli A, et al. Randomized trial of radiofrequency ablation versus conventional surgery for superficial venous insufficiency: if you don't tell, they won't know. Clinics 2016;71:650–6. https://doi.org/10.6061/clinics/2016(11)06.

[20] The Japanese Society for Vascular Surgery Database Management Committee Member, NCD Vascular Surgery Data Analysis Team. Vascular Surgery in Japan: 2014 Annual Report by the Japanese Society for Vascular Surgery. Ann Vasc Dis 2020;13:474–93. https://doi.org/10.3400/avd.ar.20-00128.

[21] Kim TI, Zhang Y, Guzman RJ, Ochoa Chaar CI. Trends of hospital-based surgery for varicose veins in the elderly. J Vasc Surg Venous Lymphat Disord 2021;9:146-153.e2. https://doi.org/10.1016/j.jvsv.2020.04.016.

[22] Castro-Ferreira R, Quelhas MJ, Freitas A, Vidoedo J, Silva EA, Marinho A, et al. Vascular training does matter in the outcomes of saphenous high ligation and stripping. J Vasc Surg Venous Lymphat Disord 2019;7:732–8. https://doi.org/10.1016/j.jvsv.2019.01.060.

[23] Prabhakar AM, Misono AS, Sheth RA, Rosenkrantz AB, Hemingway J, Hughes DR, et al. Changing Medicare Utilization of Minimally Invasive Procedures for the Treatment of Chronic Venous Insufficiency. J Vasc Interv Radiol 2017;28:818–24. https://doi.org/10.1016/j.jvir.2017.02.034.

[24] Laurikka J, Sisto T, Auvinen O, Tarkka M, Laara E, Hakama M. Varicose veins in a Finnish population aged 40-60. J Epidemiol Community Health 1993;47:355–7. https://doi.org/10.1136/jech.47.5.355.

[25] Guillaume GM, Meeus P, Dalcq V, van der Borght L, Vuylsteke ME, de Maeseneer MG. Influence of reimbursement policies on phlebological surgical practice in Belgium between 2007 and 2017. Int Angiol 2020;39. https://doi.org/10.23736/S0392-9590.20.04305-9.

[26] Galland RB, Whatling PJ, Crook TJ, Magee TR. Regional variation in varicose vein operations in England 1989-1996. Ann R Coll Surg Engl 2000;82:275–9.

[27] Maffei FHA, Magaldi C, PINHOt SZ, Lastoria S, Pinho W, Yoshida WB, et al. Varicose Veins and Chronic Venous Insufficiency in Brazil: Prevalence among 1755 Inhabitants of a Country Town. Int J Epidemiol n.d.:8.

[28] Koskinen S, Finlande, Ministry of Social Affairs and Health, National Public Health Institute (Finlande), Finlande, Centre national de recherche et de développement pour les affaires sociales et la santé. Health in Finland. Helsinki: National Public Health Institute KTL : National Research and Development Centre for Welfare and Health STAKES : Ministry of Social Affairs and Health; 2006.

[29] Schokkaert E, Van de Voorde C. Health care reform in Belgium. Health Econ 2005;14:S25–39. https://doi.org/10.1002/hec.1027.

[30] Woods KJ. The development of integrated health care models in Scotland. Int J Integr Care 2001;1. https://doi.org/10.5334/ijic.29.

[31] Zhang M, Qiu T, Bu X, Li X, Liang G, Zhang H, et al. A national survey on management of varicose veins in China. J Vasc Surg Venous Lymphat Disord 2018;6:338-346.e1. https://doi.org/10.1016/j.jvsv.2017.10.018.

11. Tables

Table 1: Absolute and relative frequencies of unilateral and bilateral surgeries for varicose veins between 2008 and 2019

Year	Unilateral Procedures		Bilateral Procedures		TOTAL
	n	(%)	n	(%)	
2008	27,484	38.08	44,688	61.92	72,172
2009	25,836	36.05	45,838	63.95	71,674
2010	25,278	33.66	49,817	66.34	75,095
2011	24,625	32.85	50,332	67.15	74,957
2012	24,262	33.07	49,109	66.93	73,371
2013	25,800	34.17	49,698	65.83	75,498
2014	30,181	38.10	49,031	61.90	79,212
2015	26,540	38.62	42,174	61.38	68,714
2016	29,492	42.79	39,431	57.21	68,923
2017	30,494	45.43	36,635	54.57	67,129
2018	35,400	47.23	39,549	52.77	74,949
2019	27,693	41.01	39,833	58.99	67,526
Total	**333,085**	**38.32**	**536,135**	**61.68**	**869,220**

Table 2: Governmental costs for varicose veins surgical treatment by geographic region in Brazil in US Dollars

Geographic Region	Total Amount	Average Amount Spent per Procedure
North	10,533,014.41	369.29
Northeast	31,901,347.77	287.24
Southeast	149,023,385.05	315.75
South	60,044,035.03	285.48
Center-West	15,126,399.43	319.53
Total	**266,628,181.69**	**306.74**

Table 3: Absolute and relative mortality by geographic region for varicose vein surgery between 2008 and 2019

Geographic Region	Procedures	Mortality	
		n	per 100,000
North	28,522	1	3.50607
Northeast	111,062	12	10.80478
Southeast	471,970	28	5.93258
South	210,327	4	1.90180
Center-West	47,339	4	8.44969
Total	**869,220**	**49**	**5.63724**

12. Figures and Figure legends

Graph 1. Distribution of procedures rates per 10,000 inhabitants exclusively dependent on the public health system per year.

Graph 2. Overall average reimbursement per surgery per year in US dollars.